Company / Cash & Equivalents
BridgeBio Pharma, Inc. Cash & Equivalents History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$570.1M
FY2025
5-year range
$356.1M / $681.1M
FY2021-FY2025
Trend
-16.3%
vs FY2024
Sector context
#36 of 207
Health Care
What the data says
BridgeBio Pharma, Inc.'s cash & equivalents of $570M is higher than 83% of companies in the Health Care sector (FY2025). Improved from $377M to $570M over the past 2 years.
Based on SEC 10-K filings.
$570M in FY2025 with a 5-year CAGR of +9.9%. Top quartile in the Health Care sector.
Improved from $377M to $570M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +14.8%
- 5-Year CAGR
- +9.9%
- 10-Year CAGR
- -
Sector benchmark
Top 17% in Health CareTop 17% of 207This company $570.1M Sector average $669.5M
▼
-14.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +9.9%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 16.3% year-over-year.
- Ranks #36 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $570.1M | -16.3% |
| FY2024 | $681.1M | +80.8% |
| FY2023 | $376.7M | +0.0% |
| FY2022 | $376.7M | +5.8% |
| FY2021 | $356.1M | +0.0% |
| FY2020 | $356.1M | -2.1% |
| FY2019 | $363.8M | -16.6% |
| FY2018 | $436.1M | +374.0% |
| FY2017 | $92.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026